Title - Relief in Sight: Understanding the Burden of Spondyloarthritis Conditions and Improving Outcomes

Program Description
This interactive online activity uses self-study and group discussion modules on a collaborative platform to examine various facets about spondyloarthritis (SpA) conditions. Learn more about differentiating SpA for a timely diagnosis and targeted treatments including IL-17 antagonists, as well as strategies for applying targeted treatment options, implementing shared decision making and multidisciplinary collaboration to promote optimal outcomes for patients with these debilitating conditions.

Intended Audiences
This activity is designed to meet the educational needs of rheumatologists, rheumatology NPs, and rheumatology PAs.

Commercial Supporters
This activity is supported by an educational grant from Lilly.

Educational Objectives
After taking part in this educational activity, clinicians should become better able to:

• Describe the clinical manifestations of SpA conditions to promptly differentiate and diagnose 
• Apply the latest clinical evidence for IL-17 antagonists for the management of SpA conditions 
• Develop strategies to optimize the shared decision-making efforts and collaboration across the multidisciplinary care team in the management of SpA conditions 

Didactic content developed by Eval Siegel, MD, FACP, FACR and Atul Deodhar, MD, FACP, FACR.
 

Accredited Provider & Accreditation Statements

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement
Med Learning Group designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Disclosure of Financial Relationships Policy
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Disclaimer
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/ 

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

Dr. Siegel discloses the following: 
Consulting fees from Abbvie, Janssen, Novartis, UCB and BMS
Speakers’ bureau for Abbvie, Janssen, Horizon and UCB
Ownership interest in Abbvie, Amgen and Lilly

Dr. Deodhar discloses the following relationships:  
Consulting/Advisory Boards: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB 
Research Grants: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB

All relevant financial relationships have been mitigated.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
 

Accredited Provider Disclosure 
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, VP Med/Sci Services & Learner Engagement, has nothing to disclose.
Michael Andria, PharmD, Medical Director of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
 

Method of Participation/Instructions
This activity is offered at no cost to participants. To obtain credit, please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline Assessment - 0.25 credit
• Self Study Module 1 - 0.50 credit
• Self Study Module 2 - 0.50 credit
• Live Group Discussion 1 - 0.75 credit
• Final Assessment - 0.25 credit
• Action Plan Development - 0.50 credit
• Group Challenge - 0.50 credit
• Live Group Discussion 2 - 0.75 credit